Predicting the effect of successful human papillomavirus vaccination on existing cervical cancer prevention programs in the United States

Philip E. Castle, Diane Solomon, Debbie Saslow, Mark Schiffman

Research output: Contribution to journalReview article

16 Citations (Scopus)

Abstract

The development of a prophylactic human papillomavirus (HPV) vaccine that potentially may eliminate a majority of cervical cancers is a landmark in cancer prevention. Cervical screening, however, will continue to play an important role for the foreseeable future. Maintaining screening at the same intensity and simply adding on the expense of vaccination would result in redundancy of prevention efforts at enormously increased costs without necessarily further reducing cervical cancer mortality. Effectively integrating vaccination and screening efforts will be a critical and evolving challenge over the next decade; this will require understanding not only the impact of vaccination on reducing cervical abnormalities but also the influence of vaccination on screening test performance.

Original languageEnglish (US)
Pages (from-to)3031-3035
Number of pages5
JournalCancer
Volume113
Issue number10 SUPPL.
DOIs
StatePublished - Nov 15 2008
Externally publishedYes

Fingerprint

Uterine Cervical Neoplasms
Vaccination
Papillomavirus Vaccines
Costs and Cost Analysis
Mortality
Neoplasms

Keywords

  • Cervical abnormalities
  • Colposcopy-guided biopsy
  • Oncogenic human papillomavirus testing
  • Positive predictive value
  • Prevention
  • Screening
  • Viral-like particle vaccines

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Predicting the effect of successful human papillomavirus vaccination on existing cervical cancer prevention programs in the United States. / Castle, Philip E.; Solomon, Diane; Saslow, Debbie; Schiffman, Mark.

In: Cancer, Vol. 113, No. 10 SUPPL., 15.11.2008, p. 3031-3035.

Research output: Contribution to journalReview article

Castle, Philip E. ; Solomon, Diane ; Saslow, Debbie ; Schiffman, Mark. / Predicting the effect of successful human papillomavirus vaccination on existing cervical cancer prevention programs in the United States. In: Cancer. 2008 ; Vol. 113, No. 10 SUPPL. pp. 3031-3035.
@article{8dccfe444efd4737ae11dd87fff852f5,
title = "Predicting the effect of successful human papillomavirus vaccination on existing cervical cancer prevention programs in the United States",
abstract = "The development of a prophylactic human papillomavirus (HPV) vaccine that potentially may eliminate a majority of cervical cancers is a landmark in cancer prevention. Cervical screening, however, will continue to play an important role for the foreseeable future. Maintaining screening at the same intensity and simply adding on the expense of vaccination would result in redundancy of prevention efforts at enormously increased costs without necessarily further reducing cervical cancer mortality. Effectively integrating vaccination and screening efforts will be a critical and evolving challenge over the next decade; this will require understanding not only the impact of vaccination on reducing cervical abnormalities but also the influence of vaccination on screening test performance.",
keywords = "Cervical abnormalities, Colposcopy-guided biopsy, Oncogenic human papillomavirus testing, Positive predictive value, Prevention, Screening, Viral-like particle vaccines",
author = "Castle, {Philip E.} and Diane Solomon and Debbie Saslow and Mark Schiffman",
year = "2008",
month = "11",
day = "15",
doi = "10.1002/cncr.23762",
language = "English (US)",
volume = "113",
pages = "3031--3035",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "10 SUPPL.",

}

TY - JOUR

T1 - Predicting the effect of successful human papillomavirus vaccination on existing cervical cancer prevention programs in the United States

AU - Castle, Philip E.

AU - Solomon, Diane

AU - Saslow, Debbie

AU - Schiffman, Mark

PY - 2008/11/15

Y1 - 2008/11/15

N2 - The development of a prophylactic human papillomavirus (HPV) vaccine that potentially may eliminate a majority of cervical cancers is a landmark in cancer prevention. Cervical screening, however, will continue to play an important role for the foreseeable future. Maintaining screening at the same intensity and simply adding on the expense of vaccination would result in redundancy of prevention efforts at enormously increased costs without necessarily further reducing cervical cancer mortality. Effectively integrating vaccination and screening efforts will be a critical and evolving challenge over the next decade; this will require understanding not only the impact of vaccination on reducing cervical abnormalities but also the influence of vaccination on screening test performance.

AB - The development of a prophylactic human papillomavirus (HPV) vaccine that potentially may eliminate a majority of cervical cancers is a landmark in cancer prevention. Cervical screening, however, will continue to play an important role for the foreseeable future. Maintaining screening at the same intensity and simply adding on the expense of vaccination would result in redundancy of prevention efforts at enormously increased costs without necessarily further reducing cervical cancer mortality. Effectively integrating vaccination and screening efforts will be a critical and evolving challenge over the next decade; this will require understanding not only the impact of vaccination on reducing cervical abnormalities but also the influence of vaccination on screening test performance.

KW - Cervical abnormalities

KW - Colposcopy-guided biopsy

KW - Oncogenic human papillomavirus testing

KW - Positive predictive value

KW - Prevention

KW - Screening

KW - Viral-like particle vaccines

UR - http://www.scopus.com/inward/record.url?scp=56449091552&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56449091552&partnerID=8YFLogxK

U2 - 10.1002/cncr.23762

DO - 10.1002/cncr.23762

M3 - Review article

C2 - 18980285

AN - SCOPUS:56449091552

VL - 113

SP - 3031

EP - 3035

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 10 SUPPL.

ER -